Vinge has advised Repligen Corporation and subsidiaries ("Repligen"), a multinational life sciences group that develops and commercializes highly innovative bioprocess technologies and systems that enable efficiency in the biopharmaceutical manufacturing process, in connection with its acquisition of Metenova Holding AB with subsidiaries (“Metenova”).

Metenova is a leading innovator and manufacturer of magnetic mixers for pharmaceutical and biotechnology applications. The company is headquartered in Mölndal, Gothenburg.

The acquisition of Metenova strengthens Repligen's fluid management portfolio, with a product line that expands on the success of Repligen's systems and fluid management assemblies.

Vinge's team mainly consisted of Jonas Bergström, Johanna Wiberg, Viktor Lennartsson, Robin Sultani (M&A), Sam Seddigh, Hanna Marberg (employment), David Olander (competition), Mathilda Persson, Mika Jordan, Arthur Kinski, Mario Saad (commercial agreements), Christoffer Nordin (Life Science/Regulatory), Lisa Hörnqvist (IT and GDPR), Stojan Arnerstål, Axel Lennartsson, Johan Gavelin (IP), Kristoffer Larson (real property), Mia Falk (compliance), Anders Leissner (sanctions/export control) and Cecilia Loctander (project assistant).

Related

Vinge has advised Bolero in connection with sale of shares in Ambea AB (publ)

Vinge has advised Bolero Holdings S.à r.l. in connection with the sale of shares in Ambea AB (publ) through an accelerated bookbuilding process carried out on 1 December 2025.
December 02, 2025

Vinge advises on the sale of Segers Fabriker

Vinge has advised the sellers in connection with the sale of Segers Fabriker AB to Norrstigen. Segers is a family-owned company in Borås with operations in Sweden, Estonia, and Ukraine, which has developed and sold workwear for hotels, restaurants, and healthcare since 1943.
December 02, 2025

Vinge has advised Intea Fastigheter in connection with a directed share issue of approximately SEK 500 million

Vinge has advised the property company Intea Fastigheter AB (publ) in connection with a directed share issue of shares of series D through which the company raises proceeds of approximately SEK 500 million before transaction costs. A part of the share issue is subject to subsequent approval at an extraordinary general meeting.
December 01, 2025